Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Gains from Sales and Divestitures: 2011-2024

Historic Gains from Sales and Divestitures for Ironwood Pharmaceuticals (IRWD) over the last 4 years, with Dec 2024 value amounting to $1.9 million.

  • Ironwood Pharmaceuticals' Gains from Sales and Divestitures rose 13.36% to $1.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.9 million, marking a year-over-year increase of 13.36%. This contributed to the annual value of $1.9 million for FY2024, which is 13.36% up from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Gains from Sales and Divestitures stood at $1.9 million for Q4 2024, which was up 13.36% from $1.7 million recorded in Q4 2023.
  • Ironwood Pharmaceuticals' Gains from Sales and Divestitures' 5-year high stood at $1.9 million during Q4 2024, with a 5-year trough of $965,625 in Q4 2020.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $1.7 million (2023), whereas its average is $1.6 million.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first declined by 25.64% in 2020, then surged by 75.82% in 2021.
  • Ironwood Pharmaceuticals' Gains from Sales and Divestitures (Quarterly) stood at $965,625 in 2020, then surged by 75.82% to $1.7 million in 2021, then declined by 21.80% to $1.3 million in 2022, then rose by 25.34% to $1.7 million in 2023, then climbed by 13.36% to $1.9 million in 2024.
  • Its Gains from Sales and Divestitures stands at $1.9 million for Q4 2024, versus $1.7 million for Q4 2023 and $1.3 million for Q4 2022.